Skip to main content
Premium Trial:

Request an Annual Quote

BlueGnome to Market Rubicon Technology for IVF Studies

NEW YORK (GenomeWeb News) – BlueGnome will market Rubicon Genomics' technology along with its microarray-based aneuploidy chromosome screening and detection systems under a new non-exclusive agreement, Rubicon said today.

BlueGnome will market the PicoPlex technology to in vitro fertilization researchers under the name SurePlex DNA Amplification System. The PicoPlex technology can obtain "the same amount of genomic data from one cell as from 10,000," the company said, enabling researchers to produce five micrograms of amplified DNA in under three hours.

"We selected PicoPlex as the basis of SurePlex due to its rapid protocol, highly representative amplification and improved consistency over other amplification methods," Nick Haan, founder and CEO of BlueGnome, said in a statement.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.